Janux Therapeutics Income Statement (2020-2026) | JANX

Income Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
0.48M1.16M1.62M1.59M2.37M1.81M2.85M2.05M1.06M2.52M2.46M1.25M8.90M0.44M10.00M3.73M
Operating items
Research & Development (Quarter)
4.74M8.41M11.17M10.18M14.09M13.74M15.43M15.87M14.92M11.89M12.24M14.07M14.90M18.61M20.81M25.05M34.66M34.63M31.55M26.81M
Selling, General & Administrative (Quarter)
2.00M3.66M3.94M4.95M5.54M6.10M5.68M6.46M6.88M6.44M6.36M7.34M7.82M17.67M8.22M9.84M10.45M10.62M10.85M11.13M
Operating Expenses (Quarter)
6.73M12.06M15.11M15.13M19.63M19.84M21.11M22.33M21.80M18.33M18.60M21.41M22.72M36.28M29.02M34.90M45.12M45.25M42.40M37.95M
Operating Income (Quarter)
-6.25M-10.90M-13.49M-13.54M-17.26M-18.02M-18.27M-20.28M-20.75M-15.81M-16.14M-20.16M-13.82M-35.84M-29.02M-34.90M-45.12M-35.25M-42.40M-34.21M
EBIT (Quarter)
-6.25M-10.90M-13.49M-13.54M-17.26M-18.02M-18.27M-20.28M-20.75M-15.81M-16.14M-20.16M-13.82M-35.84M-29.02M-34.90M-45.12M-35.25M-42.40M-34.21M
Non-operating items
Interest & Investment Income (Quarter)
0.05M0.14M0.07M0.13M0.37M1.33M2.20M2.82M3.24M4.25M4.38M5.40M7.86M7.78M8.81M11.39M11.26M10.94M10.46M9.85M
Non Operating Income (Quarter)
0.05M0.14M0.07M0.13M0.37M1.33M2.20M2.82M3.24M4.25M4.38M5.40M7.86M7.78M8.81M11.39M11.26M10.94M10.46M9.85M
Net income details
EBT (Quarter)
-6.21M-83.44M-13.42M-48.43M-54.68M-54.41M-16.41M-54.89M-54.12M-26.64M-11.76M-268.52M-292.84M-341.55M-20.22M-154.68M-132.53M-131.16M-31.95M-52.86M
Profit After Tax (Quarter)
-6.21M-10.77M-13.71M-13.41M-16.89M-16.70M-15.32M-17.46M-17.83M-11.68M-12.12M-15.95M-7.05M-28.06M-20.22M-23.51M-33.87M-24.31M-34.34M-24.36M
Income from Continuing Operations (Quarter)
-6.21M-83.44M-13.42M-48.43M-54.68M-54.41M-16.41M-54.89M-54.12M-26.64M-11.76M-268.52M-292.84M-341.55M-20.22M-154.68M-132.53M-131.16M-31.95M-52.86M
Consolidated Net Income (Quarter)
-6.21M-83.44M-13.42M-48.43M-54.68M-54.41M-16.41M-54.89M-54.12M-26.64M-11.76M-268.52M-292.84M-341.55M-20.22M-154.68M-132.53M-131.16M-31.95M-52.86M
Income towards Parent Company (Quarter)
-6.21M-83.44M-13.42M-48.43M-54.68M-54.41M-16.41M-54.89M-54.12M-26.64M-11.76M-268.52M-292.84M-341.55M-20.22M-154.68M-132.53M-131.16M-31.95M-52.86M
Net Income towards Common Stockholders (Quarter)
-6.21M-83.44M-13.42M-48.43M-54.68M-54.41M-16.41M-54.89M-54.12M-26.64M-11.76M-268.52M-292.84M-341.55M-20.22M-154.68M-132.53M-131.16M-31.95M-52.86M
Additional items
EPS (Basic) (Quarter)
-0.62-2.03-0.57-1.17-1.32-1.31-0.40-1.31-1.29-0.58-0.27-5.47-5.38-6.25-0.38-2.50-2.14-2.11-0.52-0.84
EPS (Diluted) (Quarter)
-0.62-2.03-0.57-1.17-1.32-1.31-0.40-1.31-1.29-0.58-0.27-5.47-5.38-6.25-0.38-2.50-2.14-2.11-0.52-0.84
Shares Outstanding (Quarter)
10.03M41.13M23.53M41.32M41.45M41.53M41.47M41.76M41.84M45.71M44.02M49.05M54.45M54.63M53.75M61.79M61.90M62.02M61.97M62.67M
Shares Outstanding (Diluted) (Quarter)
10.03M41.13M23.53M41.32M41.45M41.53M41.47M41.76M41.84M45.71M44.02M49.05M54.45M54.63M53.75M61.79M61.90M62.02M61.97M62.67M
EBITDA (Quarter)
-6.25M-10.90M-13.49M-13.54M-17.26M-18.02M-18.27M-20.28M-20.75M-15.81M-16.14M-20.16M-13.82M-35.84M-29.02M-34.90M-45.12M-35.25M-42.40M-34.21M
Interest Expenses (Quarter)
72.67M35.02M37.79M37.72M0.34M37.43M36.61M15.08M253.76M286.88M313.49M131.17M98.68M106.84M28.50M